Medipoint Hospitals Pvt. Ltd. Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2010
NCT01257906
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Medipoint Hospitals Pvt. Ltd. Maharashtra, India | Medipoint Hospitals Pvt. Ltd.,Pentagon Research Pvt. Ltd, 241/1, New DP Road, Aundh, Pune-411007, Maharashtra

Active Ingredients

Drugs in Phase 4 Trials (1)

mechlorethamine (mustargen) (1 trial)

Drugs in Phase 3 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Drugs in Other Trials (2)

clindamycin (cleocin) (1 trial)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4